全球酒精性肝病市场：按适应症、地区和国家分析和预测（2025 年至 2035 年）

酒精性肝病 (ARLD) 市场的主要驱动因素之一是全球过量饮酒的增加。

随着酗酒和重度饮酒现象持续上升，尤其是在年轻一代中，酒精性脂肪肝 (AFLD)、酒精性肝炎、肝硬化和肝功能衰竭等肝臟相关疾病的发生率也在上升。这一趋势导致对有效治疗方案和干预措施的需求增加，从而推动了市场的发展。此外，社会对酒精对肝臟不良影响的认识不断提高，诊断技术和支持早期发现和治疗的药物研发的进步，也进一步推动了市场的成长。

然而，ARLD 市场的成长面临许多挑战。其中最大的挑战之一是疾病的延迟诊断和漏报。许多人并不了解这种疾病，尤其是在酒精性脂肪肝 (AFLD) 等早期阶段，因为几乎没有任何主观症状。通常只有在疾病发展到肝炎或肝硬化等严重阶段后才被诊断出来。这种延迟诊断限制了早期疗育的有效性，并增加了需要肝臟移植等昂贵且侵入性治疗的风险。此外，社会对酗酒和肝病的偏见也阻碍了患者寻求治疗。在此背景下，虽然先进的治疗方法正在开发中，但缺乏广泛的早期检测是市场成长的主要障碍。

市场区隔

细分一：按适应症

• 酒精性脂肪肝
• 酒精性肝炎
• 肝纤维化
• 肝硬化

细分2：按地区

• 北美洲
• 欧洲
• 亚太地区
• 其他地区

本报告调查了全球酒精相关肝病市场，并总结了主要趋势、市场影响因素分析、法律制度、技术和专利分析、市场规模趋势和预测、各个细分市场、地区/主要国家的详细分析、竞争格局和主要企业的概况。

目录

执行摘要

第一章全球酒精性肝病市场：产业展望

• 市场趋势
• 法律规范
• 流行病学分析
• 临床试验分析
• 市场动态
  • 影响分析
  • 市场驱动因素
  • 市场挑战
  • 市场机会

2. 全球酒精性肝病市场（按适应症）

• 酒精性脂肪肝
• 酒精性肝炎
• 肝纤维化
• 肝硬化

3. 全球酒精性肝病市场（按地区）

• 北美洲
• 欧洲
• 亚太地区
  • 主要发现
  • 市场动态
  • 市场规模及预测

4. 全球酒精性肝病市场：竞争格局与公司概况

• 关键策略和发展
  • M&A
  • 协同效应活动
  • 业务扩展和资金筹措
  • 产品发布和核准
  • 其他活动
• 公司简介
  • Merck KGaA
  • Pfizer Inc.
  • Novartis AG
  • AbbVie Inc.
  • Gilead Sciences Inc.
  • Intercept Pharmaceuticals
  • Durect

第五章调查方法

Global Alcohol Related Liver Disease Market, Analysis and Forecast: 2025-2035

Alcohol-related liver disease (ARLD) is a spectrum of liver conditions that develop due to excessive alcohol consumption over time. The disease ranges from early-stage conditions such as alcoholic fatty liver disease (AFLD) to more advanced stages, such as alcoholic hepatitis, liver fibrosis, and cirrhosis. Alcohol-related liver disease occurs because the liver, which is responsible for processing alcohol, becomes overwhelmed and damaged by excessive intake. In the early stages, fatty deposits build up in the liver cells (AFLD), but as the disease progresses, it can lead to inflammation (alcoholic hepatitis), scarring (fibrosis), and eventually irreversible damage (cirrhosis), which severely impairs liver function. If left untreated, Alcohol-related liver disease can result in liver failure and increase the risk of liver cancer. Early diagnosis and lifestyle changes, such as reducing or ceasing alcohol consumption, are crucial for managing the disease and preventing its progression to more severe stages.

One of the key drivers of the alcohol-related liver disease (ARLD) market is the increasing prevalence of excessive alcohol consumption worldwide. As binge drinking and heavy alcohol use continue to rise, particularly among younger populations, the incidence of liver-related diseases such as alcoholic fatty liver disease (AFLD), alcoholic hepatitis, cirrhosis, and liver failure is also growing. This trend is leading to higher demand for effective treatment options and interventions, driving the market for Alcohol-related liver disease therapies. Additionally, greater public awareness of the harmful effects of alcohol on liver health, combined with advancements in diagnostic technologies and drug development, is encouraging early detection and treatment, further boosting market growth.

Despite the growth of the alcohol-related liver disease (ARLD) market, several challenges continue to impede its full potential. One major challenge is the late-stage diagnosis and underreporting of the disease. Alcohol-related liver disease, particularly in its early stages such as alcoholic fatty liver disease (AFLD), often presents with no symptoms, leading many individuals to remain unaware of their condition until it progresses to more severe stages such as alcoholic hepatitis or cirrhosis. This delay in diagnosis limits the effectiveness of early intervention, which is crucial for preventing further liver damage and reducing the need for costly treatments such as liver transplantation. Additionally, the social stigma surrounding alcohol use and liver disease can discourage individuals from seeking medical help, further exacerbating the problem. As a result, while treatments for advanced Alcohol-related liver disease are improving, the lack of widespread early detection remains a significant barrier to realizing the full potential of the market.

The global alcohol-related liver disease (ARLD) market is highly competitive, with several key players driving innovation and market growth. Leading companies such as Merck KGaA, Pfizer Inc., Novartis AG, AbbVie Inc., Gilead Sciences Inc., Intercept Pharmaceuticals, and Durect are at the forefront of developing cutting-edge therapies and advancing research. These companies are focusing on expanding their product portfolios to include novel drugs targeting the various stages of alcohol-related liver disease, including antifibrotic agents, anti-inflammatory treatments, and liver-protective therapies. Their commitment to innovation, alongside strategic partnerships and collaborations, is helping accelerate the development of effective treatments for alcohol-related liver disease. With the increasing prevalence of alcohol consumption and growing awareness of liver health, these industry leaders are well-positioned to capture a significant share of the alcohol-related liver disease market while improving patient outcomes through advanced therapeutic options.

Market Segmentation:

Segmentation 1: by Indication

• Alcoholic Fatty Liver Disease
• Alcoholic Liver Hepatitis
• Liver Fibrosis
• Liver Cirrhosis

Segmentation 2: by Region

• North America
• Europe
• Asia-Pacific
• Rest of the World

The global alcohol-related liver disease (ARLD) market is experiencing several key emerging trends that are reshaping the landscape, driving growth, and improving patient outcomes. One of the most significant trends is the growing focus on early diagnosis and detection. With advancements in non-invasive diagnostic technologies, such as biomarker-based blood tests and advanced imaging techniques, healthcare providers are now able to identify liver conditions such as alcoholic fatty liver disease (AFLD) at earlier stages, allowing for timely interventions. Another key trend is the development of targeted therapies, particularly antifibrotic agents for cirrhosis and novel treatments for alcoholic hepatitis, which are expanding the treatment options available to patients. Additionally, there is an increased emphasis on personalized medicine, with therapies being tailored to individual patients based on their unique genetic profiles and disease progression. The market is also being reshaped by rising public awareness of the impact of alcohol on liver health, coupled with public health initiatives aimed at reducing excessive alcohol consumption. Finally, the growing availability of liver transplantation and advancements in regenerative medicine are offering hope for patients with end-stage liver disease, contributing to the market's overall expansion.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Alcohol Related Liver Disease Market: Industry Outlook

• 1.1 Introduction
• 1.2 Market Trends
• 1.3 Regulatory Framework
• 1.4 Epidemiology Analysis
• 1.5 Clinical Trial Analysis
• 1.6 Market Dynamics
  • 1.6.1 Impact Analysis
  • 1.6.2 Market Drivers
  • 1.6.3 Market Challenges
  • 1.6.4 Market Opportunities

2. Global Alcohol Related Liver Disease Market (Indication), ($Billion), 2023-2035

• 2.1 Alcoholic Fatty Liver Disease
• 2.2 Alcoholic Liver Hepatitis
• 2.3 Liver Fibrosis
• 2.4 Liver Cirrhosis

3. Global Alcohol Related Liver Disease Market (Region), ($Billion), 2023-2035

• 3.1 North America
  • 3.1.1 Key Findings
  • 3.1.2 Market Dynamics
  • 3.1.3 Market Sizing and Forecast
    • 3.1.3.1 North America Alcohol Related Liver Disease Market, by Country
      • 3.1.3.1.1 U.S.
• 3.2 Europe
  • 3.2.1 Key Findings
  • 3.2.2 Market Dynamics
  • 3.2.3 Market Sizing and Forecast
    • 3.2.3.1 Europe Alcohol Related Liver Disease Market, by Country
      • 3.2.3.1.1 Germany
      • 3.2.3.1.2 U.K.
      • 3.2.3.1.3 France
      • 3.2.3.1.4 Italy
• 3.3 Asia Pacific
  • 3.3.1 Key Findings
  • 3.3.2 Market Dynamics
  • 3.3.3 Market Sizing and Forecast
    • 3.3.3.1 Asia Pacific Alcohol Related Liver Disease Market, by Country
      • 3.3.3.1.1 China
      • 3.3.3.1.2 Japan

4. Global Alcohol Related Liver Disease Market: Competitive Landscape and Company Profiles

• 4.1 Key Strategies and Development
  • 4.1.1 Mergers and Acquisitions
  • 4.1.2 Synergistic Activities
  • 4.1.3 Business Expansions and Funding
  • 4.1.4 Product Launches and Approvals
  • 4.1.5 Other Activities
• 4.2 Company Profiles
  • 4.2.1 Merck KGaA
    • 4.2.1.1 Overview
    • 4.2.1.2 Top Products / Product Portfolio
    • 4.2.1.3 Top Competitors
    • 4.2.1.4 Target Customers/End-Users
    • 4.2.1.5 Key Personnel
    • 4.2.1.6 Analyst View
  • 4.2.2 Pfizer Inc.
    • 4.2.2.1 Overview
    • 4.2.2.2 Top Products / Product Portfolio
    • 4.2.2.3 Top Competitors
    • 4.2.2.4 Target Customers/End-Users
    • 4.2.2.5 Key Personnel
    • 4.2.2.6 Analyst View
  • 4.2.3 Novartis AG
    • 4.2.3.1 Overview
    • 4.2.3.2 Top Products / Product Portfolio
    • 4.2.3.3 Top Competitors
    • 4.2.3.4 Target Customers/End-Users
    • 4.2.3.5 Key Personnel
    • 4.2.3.6 Analyst View
  • 4.2.4 AbbVie Inc.
    • 4.2.4.1 Overview
    • 4.2.4.2 Top Products / Product Portfolio
    • 4.2.4.3 Top Competitors
    • 4.2.4.4 Target Customers/End-Users
    • 4.2.4.5 Key Personnel
    • 4.2.4.6 Analyst View
  • 4.2.5 Gilead Sciences Inc.
    • 4.2.5.1 Overview
    • 4.2.5.2 Top Products / Product Portfolio
    • 4.2.5.3 Top Competitors
    • 4.2.5.4 Target Customers/End-Users
    • 4.2.5.5 Key Personnel
    • 4.2.5.6 Analyst View
  • 4.2.6 Intercept Pharmaceuticals
    • 4.2.6.1 Overview
    • 4.2.6.2 Top Products / Product Portfolio
    • 4.2.6.3 Top Competitors
    • 4.2.6.4 Target Customers/End-Users
    • 4.2.6.5 Key Personnel
    • 4.2.6.6 Analyst View
  • 4.2.7 Durect
    • 4.2.7.1 Overview
    • 4.2.7.2 Top Products / Product Portfolio
    • 4.2.7.3 Top Competitors
    • 4.2.7.4 Target Customers/End-Users
    • 4.2.7.5 Key Personnel
    • 4.2.7.6 Analyst View

5. Research Methodology

List of Figures

• Figure: Global Alcohol Related Liver Disease Market (by Region), $Billion, 2024 and 2035
• Figure: Global Alcohol Related Liver Disease Market Key Trends, Analysis

List of Tables

• Table: Global Alcohol Related Liver Disease Market Dynamics, Impact Analysis
• Table: Global Alcohol Related Liver Disease Market (by Region), $Billion, 2024-2035
• Table: Global Alcohol Related Liver Disease Market (by Indication), $Billion, 2024-2035